A Phase 2 interventional study of Obinutuzumab in Cryoglobulinemic Vasculitis (CV), sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 25 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.
Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Cryoglobulinemic vasculitis (CV) is a rare life threatening systemic immune-complex-mediated vasculitic syndrome. Symptoms range from arthralgia, purpura to more severe manifestations such as peripheral neuropathy, glomerulonephritis, and skin necrosis.1 CV is associated with significant morbidity and mortality. The management of non-infectious mixed CV is currently based on steroids, and anti-CD20 monoclonal antibody Rituximab (RTX). Infectious complications of immunosuppressants (IS) remain the main cause of death in CV. During the last decade, studies reported efficacy of RTX in patients with CV in 65-70% of patients as compared to 30% for other IS (azathioprine…). However, CV relapse is noted in up to 40% patients within few days to 19 months after the last RTX infusion2. Following RTX, serum levels of B lymphocyte stimulator (BLyS) significantly increased and may favour the survival of autoreactive B cell clones and relapses of CV. A recent study has shown that RTX does not reset defective early B cell tolerance checkpoints. Incomplete B cell depletion following treatment with RTX may be associated with poor clinical response.
Moreover, some patients develop a serum sickness reaction to RTX that contraindicate further use of the medication2. Thus, there are important therapeutic unmet needs in CV patients that are refractory or intolerant to RTX.
Obinutuzumab (OBZ) is a type II anti-CD20 monoclonal antibody with a glycomodified Fc, approved in 2013 for the treatment of chronic lymphocytic leukemia. Reddy et al. found that OBZ was at least 2-fold more efficient than RTX at inducing B-cell cytotoxicity in in vitro whole blood assays of patients with rheumatoid arthritis and systemic lupus erythematosus. In lupus nephritis, OBZ resulted in increased complete and partial renal responses compared with placebo when added to mycophenolate mofetil and steroids for the treatment of lupus nephritis. There is a strong rationale for using OBZ in CV. OBZ is currently used off label in CV patients intolerant to RTX and case reports pointed out its effectiveness in CV4.5. CRYOBI is the first prospective multicenter phase 2 proof-of-concept trial assessing efficacy of OBZ in CV refractory or intolerant to RTX.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,596 studies on the registry; 1,037 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Active mixed cryoglobulinemia vasculitis defined by:
or intolerant to Rituximab.
Refractory patients are defined as any of the following after a standard rituximab regimen (375 mg/m² IV weekly for 4 consecutive weeks):
Improvement: A measurable positive change in the clinical signs, symptoms, and/or functional status of the affected organ(s), compared to baseline, as assessed using the organ-specific criteria below, without fulfilling full remission requirements.
Remission: Complete disappearance of all baseline symptoms and objective abnormalities in the affected organ(s), as defined below:
"CRYOBI " protocol, version v1-2 of 26/08/2025 10/68 This document is the property of DRCI/AP-HP. All reproduction is strictly prohibited. Version 4.0 dated 31/05/2019
Pulmonary remission: complete regression of the initial symptoms with no new radiological lesions and regression of all the initial lesions.
Intolerant: Patients who experienced treatment-limiting adverse events or toxicity that required discontinuation of rituximab, despite dose modification or supportive care.
Exclusion Criteria:
Malignant neoplasm within the last 5 years other than carcinoma in situ of the cervix or excised basal cell, squamous cell carcinoma of the skin and low-grade hemopathy with no indication for a specific treatment.
"CRYOBI " protocol, version v1-2 of 26/08/2025 11/68 This document is the property of DRCI/AP-HP. All reproduction is strictly prohibited. Version 4.0 dated 31/05/2019 Carcinoma in situ of the cervix and squamous cell carcinoma of the skin should have been adequately treated before inclusion in the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Obinutuzumab
Obinutuzumab will be administered intravenously at 1000 milligrams (mg) at week 0 and week 2
Complete Clinical Response
Remission of all affected organs involved at baseline and with corticosteroid withdrawal in the absence of severe clinical relapse
Time frame: At 6 months
Frequency of adverse clinical events
Frequency and severity of adverse clinical events
Time frame: At 12 weeks
Frequency of adverse clinical events
Frequency and severity of adverse clinical events
Time frame: At 24 weeks
Frequency of adverse clinical events
Frequency and severity of adverse clinical events
Time frame: At 48 weeks
Rates of patients with complete clinical response with corticosteroid withdrawal (prednisone at 0 mg/day), partial response, and no clinical response
Time frame: At 12 weeks
Rates of patients with complete clinical response with corticosteroid withdrawal (prednisone at 0 mg/day), partial response, and no clinical response
Time frame: At 24 weeks
Rates of patients with complete clinical response with corticosteroid withdrawal (prednisone at 0 mg/day), partial response, and no clinical response
Time frame: At 48 weeks
Rate of patients with complete renal remission
Defined as proteinuria \< 0.5g/24h or proteinuria/creatininuria \< 50 mg/mmol, and improvement of GFR \> 20% if GFR \< 60 mL/min/1.73 m² at diagnosis or GFR \> 60 mL/min/1.73m² if GFR ≥ 60ml/min/1.73m² at diagnosis.
Time frame: At 12 weeks
Rate of patients with complete renal remission
Defined as proteinuria \< 0.5g/24h or proteinuria/creatininuria \< 50 mg/mmol, and improvement of GFR \> 20% if GFR \< 60 mL/min/1.73 m² at diagnosis or GFR \> 60 mL/min/1.73m² if GFR ≥ 60ml/min/1.73m² at diagnosis.
Time frame: At 24 weeks
Rate of patients with complete renal remission
Defined as proteinuria \< 0.5g/24h or proteinuria/creatininuria \< 50 mg/mmol, and improvement of GFR \> 20% if GFR \< 60 mL/min/1.73 m² at diagnosis or GFR \> 60 mL/min/1.73m² if GFR ≥ 60ml/min/1.73m² at diagnosis.
Time frame: At 48 weeks
Rate of patients without cryoglobulinemia
Time frame: At 12 weeks
Rate of patients without cryoglobulinemia
Time frame: At 24 weeks
Rate of patients without cryoglobulinemia
Time frame: At 48 weeks
Rate of patients without rheumatoid factor activity
Time frame: At 12 weeks
Rate of patients without rheumatoid factor activity
Time frame: At 24 weeks
Rate of patients without rheumatoid factor activity
Time frame: At 48 weeks
Rate of patients with normal C4 complement level
Time frame: At week 12
Rate of patients with normal C4 complement level
Time frame: At week 24
Rate of patients with normal C4 complement level
Time frame: At week 48
Rate of patients with early treatment failure
Defined as the absence of clinical response
Time frame: At week 4
Cumulative incidence of clinical relapse (severe or non-severe)
Defined by reappearance of a manifestation attributable to cryoglobulinemia vasculitis
Time frame: Up to 144 weeks
Cumulative incidence of severe clinical relapse
A severe relapse is defined by the appearance or reappearance of one of the following signs: * Extensive skin necrosis with loss of substance * Specific cardiac involvement of vasculitis (documented by EKG, troponin and/or MRI) * Specific digestive impairment of vasculitis (documented by imaging and/or endoscopy) * Affection of the central nervous system specific to vasculitis (documented by cerebral MRI) * Multiple mononeuropathy clinically defined by asymmetrical motor impairment of 2 or more nerve trunks. (Documented by electromyogram) * Severe renal impairment defined as a doubling of creatinine levels from the usual value or a glomerular filtration rate according to CKD-EPI of less than 30 ml/min/1.73m2 in the absence of prior history of creatinine levels)
Time frame: Up to 144 weeks
Cumulative incidence of mild or moderate clinical relapse
* Appearance or reappearance of purpura * Arthritis * Sensory neuropathy documented by electromyogram * Glomerulonephritis (proteinuria\>1g/24h after excluding other causes of proteinuria)
Time frame: Up to 144 weeks
Cumulative dose of prednisone
Time frame: At week 24
Cumulative dose of prednisone
Time frame: At 48 weeks
Birmingham Vasculitis Activity Score (BVAS) activity score variation
Standardized clinical tool used to quantify disease activity. It varies from 0 to 63. The higher the BVAS, the more active and severe the vasculitis. Variation assessed from baseline
Time frame: Up to 12 weeks
Birmingham Vasculitis Activity Score (BVAS) activity score variation
Standardized clinical tool used to quantify disease activity. It varies from 0 to 63. The higher the BVAS, the more active and severe the vasculitis. Variation assessed from baseline
Time frame: Up to 24 weeks
Birmingham Vasculitis Activity Score (BVAS) activity score variation
Standardized clinical tool used to quantify disease activity. It varies from 0 to 63. The higher the BVAS, the more active and severe the vasculitis. Variation assessed from baseline
Time frame: Up to 48 weeks
Variation in physical summary components of score SF-36
SF-36 assesses overall health-related quality of life across multiple domains. Each domain is scored from 0 to 100. 0 = worst possible health status 100 = best possible health status It is assessed from baseline.
Time frame: Up to 24 weeks
Variation in physical summary components of score SF-36
SF-36 assesses overall health-related quality of life across multiple domains. Each domain is scored from 0 to 100. 0 = worst possible health status 100 = best possible health status It is assessed from baseline.
Time frame: Up to 48 weeks
Variation in mental summary components of score SF-36
SF-36 assesses overall health-related quality of life across multiple domains. Each domain is scored from 0 to 100. 0 = worst possible health status 100 = best possible health status It is assessed from baseline.
Time frame: Up to 24 weeks
Variation in mental summary components of score SF-36
SF-36 assesses overall health-related quality of life across multiple domains. Each domain is scored from 0 to 100. 0 = worst possible health status 100 = best possible health status It is assessed from baseline.
Time frame: Up to 48 weeks
Cumulative incidence of infections (severe or non-severe)
From baseline
Time frame: Up to 48 weeks
Cumulative incidence of severe infections
From baseline Severe infection defined by: * Tuberculosis, pneumocystis, or cytomegalovirus, * Leading to hospitalization * Leading to life threatening or death \- Progressive multifocal leukoencephalopathy. * If PML is confirmed, study agent should be discontinued and consideration should be given to stopping immunosuppressant therapy. * Neoplasia * Serious Hypersensitivity or Infusion Reactions ≥ grade 3 CTCAE * Clinically significant, potentially life-threatening (Grade 4) adverse event (AE) that the investigator believes is definitely, possibly or probably related to study agent.
Time frame: Up to 48 weeks
Cumulative incidence of non-severe infections
From baseline Infections that do not meet the definition of a "severe infection"
Time frame: Up to 48 weeks
Cumulative incidence of non-infectious complications (cancer, lymphoma, cardiovascular event: stroke, myocardial infarction, renal replacement, …)
From baseline
Time frame: Up to 48 weeks
Variation of gammaglobulin and of CD19+ B cells levels
From baseline
Time frame: Up to 12 weeks
Variation of gammaglobulin levels
From baseline
Time frame: Up to 24 weeks
Variation of gammaglobulin levels
From baseline
Time frame: Up to 48 weeks
Overall survival
From baseline
Time frame: Up to 144 weeks
Variation of CD19+ B cells levels
From baseline
Time frame: Up to 24 weeks
Variation of CD19+ B cells levels
From baseline
Time frame: Up to 48 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for May 2028, 28 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Obinutuzumab
Cryoglobulinemia, Familial Mixed
Assistance Publique - Hôpitaux de Paris →